Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameConsun Pharma
Stock Code01681
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家在中國主要從事現代中成藥及醫用成像對比劑研究、製造及營銷為一體的藥業公司。
Listing Date2013-12-19
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國廣州廣州經濟技術開發區東區東鵬大道71號
Business Address (Hong Kong)香港德輔道中19號環球大廈22樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.chinaconsun.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 4.36 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 0.1 / shares
Offer Period2013-12-12 to 2013-12-12
Global Offering Shares250,000,000 shares
HK Public Offer Shares (Initial)25,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)225,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,000,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share5.7%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,090,000,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 12.84B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣136.2百萬元
Period-End Cash Balance人民幣81.8百萬元
Listing Expenses~HK$ 102,500,000
Listing Expenses / Funds Raised~9.4%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2010201120122013-06
Revenue 303,713389,305457,801228,390
Cost of sales -63,728-95,507-111,112-50,023
Gross profit 239,985293,798346,689178,367
Other income and gains, net 40,04317,22120,5171,082
Selling and distribution expenses -127,642-116,141-135,496-73,327
Administrative expenses -48,989-49,368-50,721-25,421
Operating profit 103,329145,407179,06280,583
Profit before tax 103,329145,407179,06280,583
Income tax expense -24,071-38,106-42,856-21,517
Profit for the year 79,258107,301136,20659,066
Profit attributable to owners 79,325107,301136,20659,066
Balance Sheet
Item 2010201120122013-06
Cash and cash equivalents 32,02164,87181,755200,865
Trade and bills receivables 204,755230,720264,391244,105
Inventories 34,92120,36022,44230,766
Total current assets 271,697315,951445,058484,596
Total assets 432,213497,021646,007715,466
Total current liabilities 174,401235,299260,347259,572
Total liabilities 184,530251,001290,829301,226
Total equity 247,683246,020355,178414,240
Equity attributable to owners 247,683246,020355,178414,240
Interest-bearing borrowings 013,600037,000
Cash Flow Statement
Item 2010201120122013-06
Net cash from operating activities 68,93856,619128,83247,175
Net cash from investing activities -16,270-29,817-111,46446,684
Net cash from financing activities -70,6856,048-48425,251
Net increase in cash -18,01732,85016,884119,110
Purchase of PP&E -17,689-31,629-37,334-30,514
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 4.9
First Day OpenHK$ 5.0
First Day Change12.29%
First Day Volume189773000.0
First Day Turnover931137000.0
Use of Proceeds
1、約393.5百萬港元(約所得款項凈額總額約40%)將用于我們的基礎設施投資:(i)興建位于廣東省廣州市的新生產基地、倉庫及配套設施,以及購買及安裝該處的生產線;(ii)購買及安裝位于內蒙古自治區通遼市生產基地的新生產設施,(iii)為位于內蒙古自治區通遼市的檢驗中心購買質量控制設備;(iv)為本集團用于生產其他藥品的現有生產線升級;及(v)為本集團的信息系統升級; 2、約196.8百萬港元(約所得款項凈額總額約20%)將用于研發活動,以開發新產品; 3、約147.6百萬港元(約所得款項凈額總額約15%)將用于擴大我們的現有市場推廣及分銷網絡,以增加我們的市場滲透水平至覆蓋更多終端客戶,如縣級醫療機構和小區及農村保健中心,并相應增加我們的市場份額; 4、約147.6百萬港元(約所得款項凈額總額約15%)將用于并購擁有腎病中藥種植能力及該等專注于腎病口服現代中成藥或醫用成像對比劑的企業。我們目前并無任何具體的并購計劃或目標,亦未有與任何潛在目標訂立任何正式協議; 5、約98.4百萬港元(約所得款項凈額總額約10%)將用于營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
中银国际亚洲有限公司 CE AET863
Overall Coordinators (1)
中银国际亚洲有限公司 CE AET863
Joint Bookrunners (1)
中银国际亚洲有限公司 CE AET863
Joint Lead Managers (1)
中银国际亚洲有限公司 CE AET863

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 景林资产管理有限公司 246,885,000 HKD — 5.70% — 6 months 2014-06-19

Directors & Management

PositionChinese nameEnglish Name
Chairman安郁寶—
Company Secretary丘志明—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股東一致行動集團楊先生、安先生及黎女士合共持股約47.8%;First Kind(由Hony Capital控制)持股22.43%。
About this page

This page shows Consun Pharma (01681) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect